These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28782482)

  • 21. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine?
    Blau R; Krivitsky A; Epshtein Y; Satchi-Fainaro R
    Drug Resist Updat; 2016 Jul; 27():39-58. PubMed ID: 27449597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Precision medicine from experimental to clinical applications in oncology].
    Normanno N
    Recenti Prog Med; 2015 Dec; 106(12):597-600. PubMed ID: 26780068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
    Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
    Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.
    Reed D; Altiok S
    Cancer Control; 2011 Jul; 18(3):188-95. PubMed ID: 21666581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
    Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
    Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinational strategies of metformin and chemotherapy in cancers.
    Zhang HH; Guo XL
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):13-26. PubMed ID: 27118574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naturally occurring molecules and anticancer combination therapies in the era of personalized medicine and economic crisis.
    Naviglio S; Della Ragione F
    Curr Pharm Des; 2013; 19(30):5325-6. PubMed ID: 23394089
    [No Abstract]   [Full Text] [Related]  

  • 30. Cisplatin resistance and opportunities for precision medicine.
    Amable L
    Pharmacol Res; 2016 Apr; 106():27-36. PubMed ID: 26804248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Principles of drug therapy of malignant tumors: the role of malignant progression in the choice of effective drugs].
    Jeney A; Rosta A
    Orv Hetil; 1999 May; 140(22):1245-9. PubMed ID: 10377736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advance in studies on molecular mechanisms of cisplatin resistance and intervention with traditional Chinese medicines].
    Liu L; Bian K
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3216-20. PubMed ID: 25522600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomics, personalized medicine, and supportive cancer care.
    Sonis ST
    Am Soc Clin Oncol Educ Book; 2015; ():9-16. PubMed ID: 25993135
    [No Abstract]   [Full Text] [Related]  

  • 34. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Editorial: Targeting of Cancer Cells and Tumor Microenvironment: Perspectives for Personalized Therapy.
    Kzhyshkowska J; Bizzarri M; Apte R; Cherdyntseva N
    Curr Pharm Des; 2017; 23(32):4703-4704. PubMed ID: 29283049
    [No Abstract]   [Full Text] [Related]  

  • 36. Targeted therapy in cancer.
    Tsimberidou AM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
    Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
    Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chemotherapy in cancer of the lung].
    Gütz S
    MMW Fortschr Med; 2006 Jun; 148(22):33-4. PubMed ID: 16821578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PARP Inhibitors in Prostate Cancer.
    Ramakrishnan Geethakumari P; Schiewer MJ; Knudsen KE; Kelly WK
    Curr Treat Options Oncol; 2017 Jun; 18(6):37. PubMed ID: 28540598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trial watch: Lung cancer trial aims to bolster personalized medicine.
    Harrison C
    Nat Rev Drug Discov; 2014 Jun; 13(6):407. PubMed ID: 24875087
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.